Citizens reiterates Lyell Immunopharma stock rating on pipeline progress

Citizens has maintained a Market Outperform rating and set a price target of $34.00 for Lyell Immunopharma (NASDAQ:LYEL) following the company's announcement of progress in its clinical trials. The firm's rating was based on an analysis of Lyell's revenue and earnings multiples. Lyell reported Q2 2026 earnings and highlighted upcoming milestones, including the anticipated data readout for the pivotal PiNACLE trial in large B-cell lymphoma and updated efficacy data for LYL273 in metastatic colorectal cancer.

The company currently has a cash position of $228 million, which is higher than its debt, with a current ratio of 5.36. However, Lyell is quickly depleting its cash reserves, as evidenced by a negative levered free cash flow of $134 million over the past year. Despite this, Citizens views Lyell's shares as an attractive investment opportunity, with potential downside to $5 and potential upside to $68.

The stock is currently trading at $13.74, down 47% over the past six months. Analysts note that the stock is slightly overvalued relative to its Fair Value, and 10 additional ProTips are available to subscribers. Analyst updates and clinical trial developments have recently focused on Lyell Immunopharma, with Stifel initiating coverage on the company with a buy rating and a price target of $44.00.